| 5150 |
Poncet’s arthritis/ tuberculous rheumatism |
28/06/2023 |
|
| 5151 |
Spina ventosa |
28/06/2023 |
|
| 5138 |
Extra-spinal osteoarticular TB |
28/06/2023 |
|
| 5126 |
test |
28/06/2023 |
|
| 5183 |
Peritoneal TB |
13/07/2023 |
|
| 5191 |
Peritoneal TB Clinical Scenarios |
13/07/2023 |
|
| 5184 |
Pancreatic TB |
13/07/2023 |
|
| 5193 |
Treatment of Abdominal TB |
13/07/2023 |
|
| 5182 |
Intestinal TB |
13/07/2023 |
|
| 5196 |
Management of Intestinal TB |
13/07/2023 |
|
| 5198 |
Management of Intestinal TB vs Chrons' Disease |
13/07/2023 |
|
| 5199 |
Management of Isolated intestinal Stricture |
13/07/2023 |
|
| 5185 |
Hepatobiliary TB |
13/07/2023 |
|
| 5201 |
Management of Hepatobiliary TB |
13/07/2023 |
|
| 5187 |
Female Genital TB |
13/07/2023 |
|
| 5205 |
Management of Female Genital TB |
13/07/2023 |
|
| 5186 |
Male Genital TB |
13/07/2023 |
|
| 5209 |
Management of Male Genital Tuberculosis |
13/07/2023 |
|
| 5181 |
Urogenital TB |
13/07/2023 |
|
| 5188 |
Urinary TB |
13/07/2023 |
|
| 5213 |
Management of Urinary TB |
13/07/2023 |
|
| 5248 |
Vision for Partnerships |
20/07/2023 |
|
| 5251 |
Importance of PSE |
20/07/2023 |
|
| 5252 |
Rationale for involving private healthcare providers |
20/07/2023 |
|
| 5253 |
Other classifications of private stakeholders |
20/07/2023 |
|
| 5254 |
Key stakeholders across the spectrum of private healthcare providers |
20/07/2023 |
|
| 5249 |
Private Sector- Meaning |
20/07/2023 |
|
| 5250 |
Scope of Public Private Mix |
20/07/2023 |
|
| 5259 |
Role of the private sector in healthcare delivery |
20/07/2023 |
|
| 5260 |
NTEP Policy promoting private sector participation |
20/07/2023 |
|
